Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent ...

Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, ...